The kidney diagnosis defined the study
FLOW randomized 3,533 participants with type 2 diabetes and chronic kidney disease meeting specified filtration and urine-albumin criteria. It compared semaglutide 1.0 mg weekly with placebo. Median follow-up was 3.4 years, after a prespecified interim analysis led to early cessation. Novo Nordisk funded the study. [1]
The eligibility details are not interchangeable with a general statement about kidney health. They identify a population with established disease and particular laboratory findings. A reader with a different diagnosis, or no kidney disease, should not assume the same estimate describes their own circumstances.
What counted as a primary event
The primary composite included kidney failure, a major sustained reduction in filtration, or death from kidney-related or cardiovascular causes. There were 331 first events with semaglutide and 410 with placebo; the hazard ratio was 0.76. The annual decline in estimated filtration was also slower with semaglutide. Serious adverse events were reported in 49.6% versus 53.8%. [1]
The composite combines several serious outcomes. Calling it only kidney failure would misdescribe what was counted. When evaluating a headline, ask for the exact list of components and whether the number describes first events, all events or participants with at least one event.
Why the regimen matters
FLOW used a specified diabetes-treatment regimen. It is not a trial of every semaglutide product or a direct comparison with the higher-dose weight-management regimen. Research doses identify the intervention tested; they are not suggestions for changing a prescription.
The early stopping should also remain part of the study description. It does not erase the randomized evidence, but the observation period is the one actually obtained. A reader should avoid projecting the same numerical effect indefinitely or treating an event reduction as a guarantee that established disease will reverse.
Filtration slope and clinical events provide complementary information. A slower average decline does not mean filtration increased for every participant, and an event reduction does not show that all laboratory values normalized. Keeping those outcomes separate helps a clinician explain what improvement realistically means in established disease.
Bring the result to the clinician managing kidney care
The most useful question is how this trial fits into the broader plan for diabetes and kidney disease. Ask which outcomes will be followed and which clinician coordinates the decisions. A separate weight-management service should have a clear process for communication rather than functioning as an isolated source of prescriptions.
Our SELECT kidney analysis covers a different population without diabetes and should be read on its own terms. Use the support guide to establish responsibilities across services. Neither a medication trial nor a provider comparison replaces individualized assessment of kidney status and existing treatment.